AMWL
American Well Corporation
AMWL offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over AMWL overall, supported by stronger fundamentals and lower modeled downside.
AMWL Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AMWL's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMWL PE Valuation
AMWL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AMWL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AMWL's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AMWL on the outlook, with more favorable revenue expectations.
AMWL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.45 | +$3.63 |
| Q2 2026 | -$4.78 | +$3.17 |
| Q1 2026 | -$5.43 | +$4.64 |
| Q4 2025 | -$5.96 | +$7.92 |
| Q3 2025 | -$7.08 | +$7.15 |
| Q2 2025 | -$7.95 | +$13.01 |
| Q1 2025 | -$10.07 | +$14.13 |
| Q4 2024 | -$13.88 | +$33.72 |
AMWL is still losing money, but far less than before: $3.45 per share over the past year, against $81.23 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AMWL on earnings quality, reporting a profit while its opponent remains loss making.
AMWL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49M | -13% |
| Q2 2026 | $52M | -27% |
| Q1 2026 | $54.9M | -18% |
| Q4 2025 | $55.3M | -22% |
| Q3 2025 | $56.3M | -7.8% |
| Q2 2025 | $70.9M | +13% |
| Q1 2025 | $66.8M | +12% |
| Q4 2024 | $71M | +0.5% |
AMWL's revenue has slid since its 2022 peak: $49M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +28 points |
| Q2 2026 | -18% | +10 points |
| Q1 2026 | -32% | +14 points |
| Q4 2025 | -45% | +15 points |
| Q3 2025 | -52% | +26 points |
| Q2 2025 | -29% | +55 points |
| Q1 2025 | -46% | +81 points |
| Q4 2024 | -60% | +20 points |
AMWL's operating margin was −24% last quarter, up 28 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMWL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AMWL on profitability, with a higher operating margin.
AMWL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11.7M | +$7.1M |
| Q2 2026 | $10.7M | +$15.4M |
| Q1 2026 | -$988K | +$24.1M |
| Q4 2025 | -$17.4M | -$3.9M |
| Q3 2025 | -$18.8M | +$13.6M |
| Q2 2025 | -$4.7M | +$17.1M |
| Q1 2025 | -$25.1M | +$34.7M |
| Q4 2024 | -$13.4M | +$28.2M |
AMWL has burned cash in almost every quarter: −$19M over the past year, against −$62M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMWL on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMWL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +299K shares |
| 1 year | +5.2% | +845K shares |
| 3 years | +19% | +2.8M shares |
| 5 years | +33% | +4.2M shares |
| Available history | +772% | +15.1M shares |
AMWL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $1,000 |
| Q3 2025 | $1,000 |
| Q2 2025 | $1,000 |
| Q1 2025 | $1,000 |
| Q4 2024 | $2,000 |
AMWL has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMWL Net Leverage
AMWL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AMWL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.2 | Neutral |
| Stochastic | 37.6 | Neutral |
AMWL's weekly RSI is 54 (neutral) and its Stochastic is 38 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMWL PE vs Healthcare Sector
AMWL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AMWL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.6 | 4.1% below |
| 20 week MA | $12.2 | 1.4% below |
| 50 week MA | $8.53 | 41% above |
| 100 week MA | $7.98 | 51% above |
| 200 week MA | $17.1 | 30% below |
AMWL's trend is mixed: it's above two of its five weekly moving averages, and 30% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AMWL on trend strength, trading above more of its moving averages.
AMWL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $460.4 | $595.0 | +29% |
| 2021 | $595.0 | $128.6 | -78% |
| 2022 | $128.6 | $61.6 | -52% |
| 2023 | $61.6 | $29.8 | -52% |
| 2024 | $29.8 | $7.80 | -74% |
| 2025 | $7.80 | $4.55 | -42% |
| 2026 YTD | $4.55 | $12.0 | +164% |
AMWL has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.